Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 11

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 11
---
 ADSs, pre-funded warrants to purchase up to an aggregate of 15,667,878ADSs, and warrants to purchase up to an aggregate of 50,000,000 ADSs in this offering, based on a combined offering price of $0.20 per ADS and accompanying warrant and $0.1999 per pre-funded warrant and accompanying warrant, the as adjusted net tangible book value of our ADSs would have been approximately $14.6 million or $0.11 per ADS, as of September 30, 2024 (an increase in net tangible book value of approximately $0.05 per ADS to our existing shareholders). If you purchase ADSs or pre-funded warrants and associated warrants in this offering, you will suffer immediate and substantial dilution of approximately $0.09 per ADS, after deducting placement agent fees and estimated offering expenses payable by us. See “Dilution” on page S-12 for a more detailed discussion of the dilution you will incur in connection with this offering. If we raise additional capital in the future, your ownership in us could be diluted. In order to raise additional capital, we may at any time, offer additional ADSs, ordinary shares or other securities convertible into or exchangeable for our ADSs or ordinary shares at prices that may not be the same as the price per ADS and associated warrant in this offering. We may sell ADSs, ordinary shares or other securities in any other offering at a price per ADS or ordinary share (as applicable) that is less than the price per ADS and associated warrant paid by investors in this offering, and investors purchasing ADSs, ordinary shares or other securities in the future could have rights superior to existing holders of our securities, including investors who purchase ADSs and associated warrants in this offering. The price per share at which we sell additional ADS or ordinary shares (as applicable), or securities convertible into ADS or ordinary shares, in future transactions may be higher or lower than the price per ADS and associated warrant in this offering. S - 5 Future sales of a substantial number of ADSs in the public market or the perception that future sales may occur, could cause the market price of the ADSs to decline. In this offering, we will sell 34,332,122 ADSs representing 514,981,830 ordinary shares, which represent approximately 26% of our outstanding ordinary shares as of January 6, 2025, after giving effect to the ordinary shares represented by the ADSs sold in this offering. In addition,